Amlodipine besylate and benazepril hydrochloride capsules is a combination of amlodipine besylate and benazepril hydrochloride. Benazeprilat, the active metabolite of benazepril, is a nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor. Benazepril is converted to benazeprilat by hepatic cleavage of the ester group. Amlodipine besylate is the besylate salt of amlodipine, a dihydropyridine calcium channel blocker. Amlodipine besylate and benazepril hydrochloride capsules are formulated in four different strengths for oral administration with a combination of amlodipine besylate equivalent to 2.5 mg, 5 mg or 10 mg of amlodipine, with 10 mg or 20 mg of benazepril hydrochloride providing for the following available combinations: 2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg and 10 mg/20 mg.
Amlodipine besylate and benazepril hydrochloride capsules is a combination capsule of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and benazepril, an angiotensin converting enzyme (ACE) inhibitor. Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension (1) in patients not adequately controlled on monotherapy with either agent
Media Articles Related to Amlobenz (Amlodipine / Benazepril)
Food container plastics linked to hypertension
Source: Hypertension News From Medical News Today [2015.07.09]
Plastic food containers and wraps containing phthalates were associated with hypertension and insulin resistance in two new studies investigating the chemicals.
Hypertension, high cholesterol, other heart disease risk factors increasing In Asia
Source: Cholesterol News From Medical News Today [2015.07.07]
Research efforts, data collection vital to improved treatmentThe prevalence of cardiovascular risk factors like hypertension, high cholesterol, and diabetes have been decreasing in the United...
Two new studies on the connection between hypertension and cognitive decline
Source: Hypertension News From Medical News Today [2015.07.03]
With the number of individuals affected by cognitive decline expected to rise over the next few decades, investigating its potential causes is of major public health interest.
Source: MedicineNet Cirrhosis Specialty [2015.05.29]
Title: Portal Hypertension
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 5/29/2015 12:00:00 AM
Source: MedicineNet sildenafil Specialty [2015.02.19]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 2/19/2015 12:00:00 AM
Published Studies Related to Amlobenz (Amlodipine / Benazepril)
Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. [2010.06]
This multicentre, double-blind, trial in subjects with severe hypertension compared the efficacy and tolerability of two parallel drug regimens: A/B (amlodipine/benazepril: 5/20 or 10/40 mg daily, if necessary) with A (amlodipine: 5 or 10 mg daily, if necessary)... We conclude that titration of amlodipine and benazepril in single-pill combinations is more effective than titration of amlodipine alone for rapid BP control in patients with severe hypertension.
An eight-week, multicenter, randomized, double-blind study to evaluate the efficacy and tolerability of fixed-dose amlodipine/benazepril combination in comparison with amlodipine as first-line therapy in chinese patients with mild to moderate hypertension. [2008.06]
CONCLUSIONS: In this group of patients, comparable antihypertensive effects were seen with the fixed-dose combination therapy, compared with amlodipine monotherapy. Both treatments appeared well tolerated in the studied population, but cough was more common in the fixed-dose combination group.
The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. [2007.03]
BACKGROUND: This study compared the efficacy and safety of amlodipine/benazepril (10/40 mg/day and 10/20 mg/day) with amlodipine 10 mg/day in patients whose blood pressure (BP) was not adequately controlled with amlodipine monotherapy... CONCLUSION: Amlodipine/benazepril combinations were well tolerated and resulted in significant BP reductions and better BP responder rates than amlodipine monotherapy.
Comparative efficacy and safety of amlodipine/benazepril combination therapy and
amlodipine monotherapy in severe hypertension. 
This multicentre, double-blind, trial in subjects with severe hypertension
compared the efficacy and tolerability of two parallel drug regimens: A/B
(amlodipine/benazepril: 5/20 or 10/40 mg daily, if necessary) with A (amlodipine:
5 or 10 mg daily, if necessary)... We conclude that titration of amlodipine and benazepril
in single-pill combinations is more effective than titration of amlodipine alone
for rapid BP control in patients with severe hypertension.
Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. 
BACKGROUND: Treatment regimens that require fewer dosage units and less frequent dosing to decrease the complexity and cost of care are among the strategies recommended to improve compliance with antihypertensive therapy. Simplifying therapy may be particularly important for elderly patients, who are more likely to have co-morbid conditions and to be taking multiple medications. OBJECTIVE: To determine rates of compliance with antihypertensive therapy and total costs of care among elderly Medicaid recipients treated with fixed-dose combination amlodipine besylate/benazepril versus a dihydropyridine calcium channel antagonist and ACE inhibitor prescribed as separate agents (free combination)... CONCLUSION: Use of fixed-dose amlodipine besylate/benazepril HCl by elderly Medicaid recipients was associated with improved compliance and lower healthcare costs compared with a dihydropyridine calcium channel antagonist and ACE inhibitor prescribed as separate agents.
Clinical Trials Related to Amlobenz (Amlodipine / Benazepril)
Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension [Completed]
This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult
Chinese patients with mild to moderate essential hypertension. Patients whose blood pressure
is not adequately controlled with benazepril monotherapy during a 4 week run-in period will
be randomly allocated to double blind treatment over 8 weeks with either a combination of
benazepril/hydrochlorothiazide per day or continuation of benazepril per day.
Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM) [Active, not recruiting]
The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is
superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive
subjects with Type 2 diabetes mellitus (DM) and diabetic nephropathy
Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors [Recruiting]
RATIONALE: Benazepril hydrochloride, lisinopril, ramipril, and losartan potassium may help
lower blood pressure.
PURPOSE: This phase II trial is studying how well benazepril hydrochloride, lisinopril,
ramipril, or losartan potassium works in treating hypertension in patients with solid
Preventing Microalbuminuria in Type 2 Diabetes [Recruiting]
In people with type 2 diabetes, microalbuminuria is a strong, independent risk factor for
diabetic nephropathy and cardiovascular morbidity and mortality. ACE inhibitor therapy
decreased the risk of microalbuminuria in hypertensive subjects with type 2 diabetes and
normoalbuminuria by about 40%. Available data suggest that angiotensin II receptor blockers
(ARBs) might have a similar renoprotective effect and that this effect might be increased by
combined ACE inhibitor therapy.
The study will evaluate the effects, at similar blood pressure control (systolic/diastolic
<130/80 mmHg), for a period of three years, of dual renin-angiotensin-system (RAS) blockade
by benazepril and valsartan combination therapy as compared to single RAS blockade by
benazepril or valsartan alone on microalbuminuria and cardiovascular events in high-risk
patients with type 2 diabetes, creatinine <1. 5 mg/dl, no evidence of microalbuminuria but at
high risk of renal disease, with hypertension and a urinary albumin excretion between 7 and
19 microgram/min. The relationship between albuminuria and cardiovascular outcomes will also
The study is expected to show a more effective prevention of microalbuminuria and
cardiovascular events with combined than with single drug ACE inhibitor or ARB therapy. As
compared to ACE inhibitor, ARB therapy is expected to have a similar effect on
microalbuminuria, but an inferior cardioprotective effect. Applied to clinical practice, the
findings should help preventing renal and cardiovascular complications, and related
treatment costs, of type 2 diabetes.
A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril [Active, not recruiting]